Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Research & Development (2020 - 2025)

Caribou Biosciences has reported Research & Development over the past 6 years, most recently at $23.8 million for Q4 2025.

  • Quarterly Research & Development fell 21.83% to $23.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.4 million through Dec 2025, down 15.92% year-over-year, with the annual reading at $109.4 million for FY2025, 15.92% down from the prior year.
  • Research & Development was $23.8 million for Q4 2025 at Caribou Biosciences, up from $22.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $35.5 million in Q1 2025 and troughed at $10.2 million in Q1 2021.
  • The 5-year median for Research & Development is $25.7 million (2022), against an average of $24.4 million.
  • Year-over-year, Research & Development soared 156.2% in 2021 and then fell 26.36% in 2025.
  • A 5-year view of Research & Development shows it stood at $15.1 million in 2021, then skyrocketed by 70.31% to $25.7 million in 2022, then increased by 21.54% to $31.3 million in 2023, then fell by 2.61% to $30.5 million in 2024, then fell by 21.83% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Research & Development are $23.8 million (Q4 2025), $22.4 million (Q3 2025), and $27.7 million (Q2 2025).